Akebia Therapeutics price to sales ratio AKBA

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 0.7×
7-year median: 1.8×
Against its 7-year history: 20th; percentile: 0 is its lowest day, 100 its highest
7-year range: 0.2× to 5.6×
Peer median: 1.4×

Akebia Therapeutics' price to sales ratio is 0.7× as of Oct 23, 2026.

That is below its 7-year median of 1.8×, lower than on 80% of days in the last 7 years.

Over that time it ranged from 0.2× in Nov 2022 to 5.6× in Jun 2025.

The median for 10 large drugmakers of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.7×	0.7×	1.8×
2025	2.0×	1.8×	5.6×
2024	n/m a value too high to mean anything
2023	0.7×	0.3×	0.7×
2022	0.4×	0.2×	2.2×
2021	1.9×	1.4×	2.6×
2020	1.3×	0.9×	4.9×
2019	2.4×	1.2×	3.0×

Against its peers

Companies in Drug Manufacturers - General nearest Akebia Therapeutics' size, closest first, today.

Company	Price to sales ratio
AKBAAkebia Therapeutics	0.7×
NATRNatures Sunshine Products	0.4×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
ARVNArvinas	1.5×
ATNMActinium Pharmaceuticals	n/m
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	0.9×
Peer median	1.4×

Where Akebia Therapeutics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Akebia Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.